JnJ to discontinue Phase 3 VENTURA development program evaluating aticaprant for major depressive disorder Ruchika Sharma7 March 2025 1:30 PM ISTTitusville: Johnson & Johnson has announced the decision to discontinue the Phase 3 VENTURA development program evaluating aticaprant as an...
JnJ names Darren Snellgrove as Vice President, Investor Relations Ruchika Sharma5 March 2025 12:51 PM ISTNew Brunswick: Johnson & Johnson has announced the appointment of Darren Snellgrove to Vice President of Investor Relations. Jessica Moore,...
JnJ to resume US VARIPULSE cases Ruchika Sharma20 Feb 2025 9:30 AM ISTNew Brunswick: Johnson & Johnson will resume the limited market release of VARIPULSE in the United States after a comprehensive...
Johnson & Johnson MedTech launches CEREGLIDE 92 Catheter System for Acute ischemic stroke Ruchika Sharma13 Feb 2025 4:54 PM ISTIrvine: Johnson & Johnson MedTech, an emerging leader in neurovascular care, has announced the launch of the CEREGLIDE 92 Catheter System, a...
JnJ Spravato gets USFDA nod as monotherapy for adults with treatment-resistant depression Ruchika Sharma22 Jan 2025 11:35 AM ISTTitusville: Johnson & Johnson has announced the U.S. Food and Drug Administration (FDA) approval of a supplemental New Drug Application...
JnJ initiates submission of New Drug Application with USFDA for TAR-200 for BCG-unresponsive high-risk non-muscle-invasive bladder cancer Ruchika Sharma16 Jan 2025 12:30 PM ISTRaritan: Johnson & Johnson has announced it has initiated the submission of an original New Drug Application with the U.S. Food and Drug...
Controversy erupts over sugary drink display at ORSL stall during pedicon conference Yakshi Chugh15 Jan 2025 6:15 PM ISTThe recently held annual conference of the Indian Academy of Pediatrics (IAP) led to a controversy after the event included an exhibition stall for...
JnJ to acquire Intra-Cellular Therapies for USD 14.6 billion Ruchika Sharma15 Jan 2025 11:30 AM ISTNew Brunswick: Johnson & Johnson and Intra-Cellular Therapies, Inc. have announced that they have entered into a definitive agreement under...
Promotion of Sugary Drinks? ORSL Stall at Pedicon Conference Leads to Controversy Barsha Misra14 Jan 2025 5:34 PM ISTHyderabad: The recently held annual conference of the Indian Academy of Pediatrics (IAP) led to a controversy after the event included an...
JnJ Nipocalimab gets USFDA Priority Review designation for generalized myasthenia gravis Ruchika Sharma12 Jan 2025 3:30 PM ISTSpring House: Johnson & Johnson has announced the nipocalimab Biologics License Application (BLA) has received Priority Review designation...
JnJ temporarily pauses rollout of Varipulse heart device in US Ruchika Sharma11 Jan 2025 5:35 PM ISTJohnson & Johnson has announced a temporarily pause in the rollout of its Varipulse heart device in the United States as it investigates four...
JnJ Posdinemab gets USFDA Fast Track Designation for treatment of Alzheimer's disease Ruchika Sharma9 Jan 2025 1:30 PM ISTPosdinemab is an investigational monoclonal antibody that targets the mid-domain of Alzheimer's disease-specific phosphorylated tau.
